Abliva AB (publ) (NEVPF) Stock Price, News & Analysis

Company Overview

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.03
• 52-Week Range: $0.01 to $0.04
• Volume: N/A
• Average Volume: 4,445 shs
• Market Capitalization: $11.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NEVPF Stock Analysis - Frequently Asked Questions

How have NEVPF shares performed this year?

Abliva AB (publ)'s stock was trading at $0.0360 at the beginning of the year. Since then, NEVPF stock has decreased by 22.2% and is now trading at $0.0280.
View the best growth stocks for 2025 here.

How do I buy shares of Abliva AB (publ)?

Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NEVPF
• CIK: N/A
• Web: www.neurovive.com
• Phone: (646) 275-6220
• Fax: 46-4-688-883-48
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -117.92%
• Return on Assets: -102.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,128.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 403,010,000
• Free Float: N/A
• Market Cap: $11.28 million
• Optionable: Not Optionable
• Beta: -1.18